AI-supported bone marrow diagnostics

Cancilico is a Dresden-based health tech startup founded in 2023 as a spin-off of the EKFZ for digital health at the Technical University of Dresden and Dresden University Hospital. Its mission is to bring state-of-the-art AI technology to routine hematology laboratories to improve the care of blood cancer patients worldwide and advance the development of digital biomarkers in hematology. 

Following a successful seed funding round in 2025, Cancilico aims to accelerate its mission to establish its AI-based diagnostic software MyeloAID as a standard tool for improving the standard of care for blood cancer patients worldwide and accelerating the development of digital biomarkers for hematological malignancies. MyeloAID aims to revolutionize the diagnosis of hematological malignancies by analyzing bone marrow samples with unprecedented speed and accuracy using advanced artificial intelligence. The underlying data model of Cancilico's AI diagnosis is based on a large validated dataset of various malignancies as well as data from healthy individuals. Partnerships with hematopathology centers further improve the data model, and collaboration with pharmaceutical partners is showing initial results for accelerated development of biomarkers and treatment options for hematological malignancies.

Especially in times when we are faced with a shortage of trained hematologists, such supportive technologies are urgently needed to ensure clinical availability and precision medicine. A special feature of MyeloAID is its design as a platform-independent solution. The technology can be implemented on any commercially available imaging microscope or scanner, allowing laboratories to improve their current diagnostic capabilities without having to replace their existing hardware infrastructure. In addition, AI diagnosis is already available and is being used as an RUO variant via Smart In Media's PathoZoom^® Scan & LiveView Suite.

Cancilico is deeply rooted in Saxony's life science ecosystem, collaborates with the regional biotech network Biosaxony, and makes an important contribution to the SaxoCell and SEMECO Clusters4Future initiatives. Within these clusters, start-ups such as Cancilico can further develop their strong founding momentum and combine it with fast translation pathways.